Loading...
Market
How many major pharmaceutical companies will announce similar cost reductions for their HIV treatments by end of 2024?
2
Resolution / Starting Odds
None • 25%
1-2 companies • 25%
3-5 companies • 25%
More than 5 companies • 25%
Official press releases from pharmaceutical companies or reputable news sources
Story
Gilead HIV Treatment Could Be Made for $26 to $40 Annually, 1,000 Times Cheaper
Jul 23, 2024, 01:25 PM
A new analysis reveals that a Gilead Sciences HIV treatment, lenacapavir, could be produced for as little as $26 to $40 per person each year, significantly lower than its current price of over $40,000. Researchers highlight that this 'vaccine-like' drug has the potential to both prevent and suppress HIV, offering a groundbreaking advancement in HIV treatment. The cost reduction, which equates to approximately Ksh. 5280 and makes the treatment 1,000 times cheaper, could make the treatment accessible to a broader population, potentially revolutionizing HIV care globally.
View original story
Similar markets
None • 25%
1 company • 25%
2 companies • 25%
3 or more companies • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
Both • 25%
Neither • 25%
GSK • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
None • 25%
1-2 • 25%
3-4 • 25%
5 or more • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
More than 4 companies • 25%
0-2 companies • 25%
3-5 companies • 25%
6-8 companies • 25%
More than 8 companies • 25%
None • 25%
1-2 companies • 25%
3-4 companies • 25%
5 or more companies • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
Other • 25%
Yes • 50%
No • 50%
